with reference to the present invention which is a tissue regenerative biological composition 100 made from bone marrow 200 , it is believed best understood by the methods used to process and recover the biological composition , as illustrated in the fig1 - 6 . the first steps are to collect , recover and process bone marrow 200 from a cadaver donor . to do this , the spine is removed aseptically from the cadaver and the resultant spine segment is covered by cold media . the cold media has 0 . 5 ml of heparin ; 10 , 000 units / ml per 500 ml of dmem . dmem is a sterile solution with low glucose ( 1 g / l ), sodium pyruvate ; without l - glutamine , or hepes . this cold media is used for packaging the spine segments for later processing . at this point the spine segment includes a plurality of vertebral bodies 202 . the clinical technician must remove as much soft tissue as possible and cut each vertebral body 202 with a saw . these vertebral bodies 202 , once cleaned , of all adherent soft tissue around the cortical surfaces will look as shown in fig1 . once a cleaned vertebral body 202 is obtained , the next step involves cutting each vertebral body 202 into pieces , each piece 204 roughly 1 cm 3 . the cut pieces 204 being immersed in a packing media 400 . the exemplary packing media can be dmem with 0 . 5 ml heparin and 1 . 25 ml of dnase added . once all the vertebral bodies 202 have been cut , the pieces 204 are taken to the bone grinder . the bone is ground into 4 - 10 mm pieces using packing media 400 to help the pieces go through the grinder . the ground bone 206 ( bulk cortical - cancellous crushed ) and all of the packing media 400 , estimated volume of 500 ml are transferred into a jar 300 where 0 . 5 - 1 . 0 ml of gentamicin is added to the jar 300 with ground bone 206 and packing media 400 . at this point , the crushed bone 206 , including cellular soft marrow 200 , is intermixed . the step of mechanically separating these cellular components of bone marrow 200 from the cadaverous bone is next performed . transferring the bulk cortical - cancellous bone chips into a new jar with a cbt - mixer in the jar . the bulk cortical - cancellous bone chips 206 will go through four cycles as summarized in the table below . each cycle , after cycle 1 , contains three steps using a bone tumbler 500 and sieve set 600 . the sieve set 600 has screens 602 of various sizes , for example 500 μm and 180 μm , as shown in fig5 . in cycle 1 , the decanted fluid 210 is discarded . to best understand this , an exemplary fig7 shows conical tubes with the decanted fluids after each cycle followed by ficoll separation . tumble 1 or cycle 1 has most of the unwanted cells and debris as evidenced by its dark and red appearance whereas each subsequent cycle 2 , 3 and 4 are progressively cleared . this fig7 is only to illustrate the effects of multiple tumbles 1 - 4 and the value in discarding the decanted liquid 210 after the first tumble 1 . after each subsequent sieving of the bulk bone material 206 , the decanted fluid 212 , 214 , 216 containing the mixture with whole cells is collected and put into a collection jar . when the next three cycles are complete and the decanted fluid is all placed in the collection jar comingling the fluids 212 , 214 and 216 to form a decanted fluid 220 . then the centrifugation of the combined decanted fluid 220 occurs by placing the fluid 220 in a number of 250 ml conical tubes using a 100 ml pipette . the centrifuge is programmed to 280 × g for 10 minutes at room temperature , preferably about 20 degrees c . the fluid 220 is passed through a blood filter to further remove any bone or spicules or clumps from the suspended cells . this completes the step of centrifuging and filtering . at this point , the mixture including whole cells 240 has been separated from the soft marrow tissue 200 and the remaining cancellous and cortical bone is discarded . after this as shown in fig6 , the step of separating the cells 240 from the non - whole cellular components by a density centrifugation occurs . the whole cells 240 are in the interface and the non - whole cell components are in the supernatant above the interface . the mixture including is placed in 50 ml conical tubes 20 with ficoll 800 and undergoes a ficoll - paque separation under centrifugation wherein a cell density gradient is established by spinning at 400 × g for 30 minutes at room temperature , preferably about 20 degrees c . the mixture includes cellular or non - cellular components or a combination thereof . all fluid 211 above the interface is removed include the desired non - whole cell components which exclude the whole cells 240 , 250 . typically , non - whole cell fragments , or membrane components have a diameter of 40 - 100 nm and can be separated within a density of 1 . 13 - 1 . 19 g / ml in a sucrose solution , and can be sedimented by centrifugation at 100 , 000 g . in fact , these fragments , or cell fractions , or microvesicles , have been collectively referred to as exosomes . ranging in size from 20 - 1000 nm in diameter , they have been similarly referred to as nanoparticles , microparticles , shedding microvesicles , apoptotic blebs , and human endogenous retroviral particles . there are few firm criteria distinguishing one type of microvesicle from the other . following removal of the cell fraction , the supernatant is further filtered through 0 . 45 and 0 . 2 μm filters . exosomes are further collected and separated within the suspension in multiple centrifugation steps with increasing centrifugal strength to sequentially pellet cells ( 300 g ), microvesicles ( 10 , 000 g ) and ultimately exosomes ( 100 , 000 g ). cells are deliberately removed to achieve the non - whole cell fragments and microvesicles . subsequent separation using density gradient - based isolation , using sucrose or commercially available prep can be applied to obtain more pure exosome preparations . recent reports encouraging the use of iodixanol - based gradients for improved separation of exosomes from viruses and small apoptotic bodies are considerations left open to be adopted or adapted in refinement . differing from sucrose , iodixanol forms iso - osmotic solutions at all densities , thus better preserving the size of the vesicles in the gradient , and both technologies are available to best isolation technology . in addition to these traditional isolation techniques , easy - to - use precipitation solutions , such as exoquick ™ and total exosome isolation ™ ( tei ), that have been commercialized reduce the need for expensive equipment or technical know - how . although their mode - of - action has not been disclosed or validated , these kits are commonly used . once the mixture is completed , the method can include additional steps . this leads to the use of a bone blend 102 shown in fig1 , preferably from the same vertebral bone or at least bone from the same donor . when the mixture is prepared , it can have whole cells or even no whole cells , but will have the mechanically selected non - whole cellular components including vesicular components and active and inactive components of biological activity , cell fragments , cellular excretions , cellular derivatives , and extracellular components . in one embodiment , the composition includes the whole cells in the mixture . in that embodiment , it is possible to provide bone particles with the mixture either in the mixture or separately to be combined at the time of use . in one embodiment , the bone is ground to a particle size of 100 - 300 μm , see fig1 . the bone mixture has 1 . 5 cc of mineralized cancellous bone 104 , 1 . 5 cc of mineralized cortical bone 105 and 2 . 0 cc of demineralized cortical bone 106 yielding 30 percent , 30 percent and 40 percent respectively of the total 5 cc ( 5 gram ) of bone material 102 . the ranges coincide with the 1 cc of mixture when resuspended in 3 cc of saline to provide a bone particle and mixture for implantation , which can be by packing , injection , scaffolding or any other suitable means , into a patient in a fracture healing procedure , by way of example . other ranges of bone particle sized and mixture can be employed depending on the application which , in this example , was bone regeneration . lower volumes and concentrations may be more suited for less intrusive bone repairs or more if larger if larger amounts of material are needed as in a hip defect or repair . variations in the present invention are possible in light of the description of it provided herein . while certain representative embodiments and details have been shown for the purpose of illustrating the subject invention , it will be apparent to those skilled in this art that various changes and modifications can be made therein without departing from the scope of the subject invention . it is , therefore , to be understood that changes can be made in the particular embodiments described , which will be within the full intended scope of the invention as defined by the following appended claims .
a biological composition has a mixture of mechanically selected allogeneic biologic material derived from bone marrow . the mixture has non - whole cellular components including vesicular components and active and inactive components of biological activity , cell fragments , cellular excretions , cellular derivatives , and extracellular components . the mixture including non - whole cell fractions including one or more of exosomes , transcriptosomes , proteasomes , membrane rafts , lipid rafts . the mixture is compatible with biologic function .